Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis
Philipp Diehl, Christoph Bode, Daniel Duerschmied Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Freiburg, Germany Abstract: Vorapaxar (ZONTIVITY™, formerly known as SCH 530348) is a specific, orally active antagonist of the protease-activated receptor-1 (P...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Dove Medical Press,
2015-08-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
Connect to this object online.3rd Floor Main Library
| Call Number: |
A1234.567 |
|---|---|
| Copy 1 | Available |